The DOI matches its Crossref record; 125 of the 125 references it cites were found in a registry or an index.
The clinical development of MEK inhibitors
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mammalian MAP kinase signalling cascades
Chang, L., & Karin, M. (2001) · Nature · doi:10.1038/35065000 · Cited by 5,111
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
Flaherty, K. T., Infante, J. R., Daud, A., Gonzalez, R., Kefford, R. F., Sosman, J., Hamid, O., Schuchter, L., Cebon, J., Ibrahim, N., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1210093 · Cited by 2,810
Mitogen-activated protein kinase pathways
Robinson, M. J., & Cobb, M. H. (1997) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(97)80061-0 · Cited by 2,474
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
Nazarian, R., Shi, H., Wang, Q., Kong, X., Koya, R. C., Lee, H., Chen, Z., Lee, M.-K., Attar, N., Sazegar, H., et al. (2010) · Nature · doi:10.1038/nature09626 · Cited by 2,192
Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
Flaherty, K. T., Robert, C., Hersey, P., Nathan, P., Garbe, C., Milhem, M., Demidov, L. V., Hassel, J. C., Rutkowski, P., Mohr, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203421 · Cited by 2,160
A Comprehensive Survey of Ras Mutations in Cancer
Prior, I. A., Lewis, P. D., & Mattos, C. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2612 · Cited by 2,063
Cowley, S. (1994) · Cell · doi:10.1016/0092-8674(94)90133-3 · Cited by 1,966
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
Bollag, G., Hirth, P., Tsai, J., Zhang, J., Ibrahim, P. N., Cho, H., Spevak, W., Zhang, C., Zhang, Y., Habets, G., et al. (2010) · Nature · doi:10.1038/nature09454 · Cited by 1,831
Signal Transduction through MAP Kinase Cascades
(1998) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)60765-4 · Cited by 1,759
ERK1/2 MAP kinases: Structure, function, and regulation
Roskoski, R. (2012) · Pharmacological Research · doi:10.1016/j.phrs.2012.04.005 · Cited by 1,650
Research works printed but not linked: 11
- Mehra, R. et al. First-in-human phase I study of the ALK inhibitor LDK378 in advanced solid tumors [abstract]. J. Clin. Oncol. 30 (Suppl.), a3007 (2012). · doi:10.1200/jco.2012.30.15_suppl.3007
- Harding, J. J. et al. Vemurafenib (VEM) in patients (pts) with BRAF-mutant melanoma and brain metastases (mets) [abstract]. J. Clin. Oncol. 31 (Suppl.), a9060 (2013). · doi:10.1200/jco.2013.31.15_suppl.9060
- Jain, N, C. et al. Phase II study of the oral MEK inhibitor selumetinib (AZD6244) in advanced acute myeloid leukemia (AML) [abstract]. J. Clin. Oncol. 30 (Suppl.), a6582 (2012).
- Hochster, H. S. et al. The MEK inhibitor selumetinib ([SEL], AZD6244, ARRY-142886) plus irinotecan (IRI) as second-line therapy for KRAS-mutated (KRASm) metastatic colorectal cancer (CRC) [abstract]. J. Clin. Oncol. 31 (Suppl.), a3587 (2013). · doi:10.1200/jco.2013.31.15_suppl.3587
- Gupta, A. et al. DOC-MEK: a double-blind randomized phase II trial of docetaxel with or without selumetinib (AZD6244; ARRY-142886) in wt BRAF advanced melanoma [abstract]. J. Clin. Oncol. 31 (Suppl.), a9068 (2013). · doi:10.1200/jco.2013.31.15_suppl.9068
- Rosen, L. S. et al. A phase 1 dose-escalation study of XL518, a potent MEK inhibitor administered orally daily to subjects with solid tumors [abstract]. J. Clin. Oncol. 26 (Suppl.), a14585 (2008). · doi:10.1200/jco.2008.26.15_suppl.14585
- Van Laethem, J. L. et al. A phase I/II study of the MEK inhibitor BAY 86-9766 (BAY) in combination with gemcitabine (GEM) in patients with nonresectable, locally advanced or metastatic pancreatic cancer (PC): phase I dose-escalation results [abstract]. J. Clin. Oncol. 30 (Suppl.), a4050 (2012). · doi:10.1200/jco.2012.30.15_suppl.4050
- Infante, J. R. et al. A randomized, double-blind, placebo-controlled trial of trametinib, a MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas [abstract]. J. Clin. Oncol. 30 (Suppl.), a291 (2013). · doi:10.1200/jco.2013.31.4_suppl.291
- Ahmed, S. R. et al. A phase I study determining the safety and tolerability of combination therapy with pazopanib, a VEGFR/PDGFR/raf inhibitor, and GSK1120212, a MEK inhibitor, in advanced solid tumors enriched with patients with advanced differentiated thyroid cancer [abstract]. J. Clin. Oncol. 30 (Suppl.), TPS3117 (2012). · doi:10.1200/jco.2012.30.15_suppl.tps3117
- Sosman, J. A. et al. First-in-human, multicenter, dose-escalation, phase I study of the investigational drug TAK-733, an oral MEK inhibitor, in patients (pts) with advanced nonhematologic malignancies and melanoma [abstract]. J. Clin. Oncol. 29 (Suppl.), TPS145 (2011). · doi:10.1200/jco.2011.29.15_suppl.tps145
- Adjei, A. A. et al. Phase I, dose-escalation study of the investigational drug TAK-733, an oral MEK inhibitor, in patients (pts) with advanced solid tumors [abstract]. J. Clin. Oncol. 31 (Suppl.), a2528 (2013). · doi:10.1200/jco.2013.31.15_suppl.2528
Cited by
Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors
Jia, Y., Yun, C.-H., Park, E., Ercan, D., Manuia, M., Juarez, J., Xu, C., Rhee, K., Chen, T., Zhang, H., et al. (2016) · Nature · doi:10.1038/nature17960 · Cited by 886
MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road
Caunt, C. J., Sale, M. J., Smith, P. D., & Cook, S. J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc4000 · Cited by 606
Garbe, C., Peris, K., Hauschild, A., Saiag, P., Middleton, M., Bastholt, L., Grob, J.-J., Malvehy, J., Newton-Bishop, J., Stratigos, A. J., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.05.005 · Cited by 605
Bauer, R. A. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.05.005 · Cited by 534
Therapeutic strategies to target RAS-mutant cancers
Ryan, M. B., & Corcoran, R. B. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0105-0 · Cited by 420
Metadata
- Authors
- Zhao, Y., & Adjei, A. A.
- Venue
- Nature Reviews Clinical Oncology
- Published
- 2014-05-20
- Volume
- 11
- Issue
- 7
- Pages
- 385-400
- ISSN
- 1759-4774 (ISSN-L)
- 1759-4782
- OpenAlex
- W1991401350
- Cited by
- 400
- References
- 125
- FWCI
- 2.85
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The clinical development of MEK inhibitors. https://app.cochat.ai/papers/10.1038/nrclinonc.2014.83
- The paper
- Zhao, Y., & Adjei, A. A. (2014). The clinical development of MEK inhibitors. Nature Reviews Clinical Oncology. https://doi.org/10.1038/nrclinonc.2014.83
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.